Alkem Labs: Hold on till growth gets a new boost
- CDMO and medtech segments are expected to supplement Alkem’s base-business growth over the long term
- Long-term growth hinges on CDMO and medtech expansion, affecting Alkem Laboratories investors
← Top stories
ALKEM
Alkem Laboratories Limited · ₹5,274 −1.0% on 25 Sept · 1M −0.6% · 3M −2.6% · 2 stories in 60 days · 0 positive · 1 negative
Open the company tag: stories, tone, the tags it comes with →
Price and news
NSE daily close · markers = sessions where news first tradedPositive newsNegative newsNeutral
Alkem Laboratories CFO Nitin Agrawal resigns
- Nitin Agrawal resigned to pursue new professional opportunities
- Alkem shares fell over 2% after the resignation
- Leadership uncertainty may weigh on Alkem Laboratories shares